Press release

Latest Advanced Wound Care Innovations and Research from Organogenesis to be Highlighted at SAWC Spring | WHS 2020 Virtual Meeting

CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the

articleOrganogenesis Holdings Inc.July 23, 20203/company/organogenesis-holdings-inc/news/latest-advanced-wound-care-innovations-and-research-from-organogenesis-to-be
Latest Advanced Wound Care Innovations and Research from Organogenesis to be Highlighted at SAWC Spring | WHS 2020 Virtual Meeting

About this update from Organogenesis Holdings Inc.

[{"type":"text","content":"CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its Apligraf®, Affinity®, Dermagraft®, Nushield® and PuraPly® AM product lines will be showcased at the 2020 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society Virtual Experience, held July 24-26.\n As a Platinum Sponsor for this year’s event, Organogenesis will support the Innovation Theater event, “Elevating the Standard of Care with Innovative Solutions” on Sunday, July 26 from 11:10 a.m. – 12 p.m. ET. The virtual event will be led by Dot Weir, RN, CWON, CWS; Nicholas Todd, DPM; and Shaun Carpenter, MD, FAPWCA, CWSP. Organogenesis will also host several virtual Private Networking Suites where attendees can watch product applications and ask industry experts questions. Additionally, visitors to the Organogenesis virtual exhibit booth will have the opportunity to learn about the Company's product portfolio and its latest advances in wound care. “As a leading sponsor of this year’s meeting, we are excited to share the latest research from our innovative product portfolio and support a dynamic lineup of virtual education events,” said Patrick Bilbo, Chief Operating Officer at Organogenesis. “We look forward to this opportunity to connect with other thought leaders who are advancing the science and practice of wound healing.” POSTER PRESENTATIONS OF INTEREST INCLUDE: A Retrospective, Comparative Effectiveness Analysis of a Bilayered Living Cellular Construct and an Acellular Fetal Bovine Collagen Dressing in the Treatment of Venous Leg UlcersGary Gibbons, MD; Michael L. Sabolinski, MD Comparative Effectiveness of a Bilayered Living Cellular Construct and a Fetal Bovine Collagen Dressing in the Treatment of Pressure InjuriesOscar M. Alvarez, PhD; Michael L. Sabolinski, MD A Comparative Effectiveness Research Study of a Purified Native Cross-Linked ECM plus Polyhexamethylene Biguanide (PHMB) Antimicrobial and a Viable Cryopreserved Placental Membrane Allograft for use in Venous Leg Ulcers - a Non-Inferiority AnalysisMichael L. Sabolinski, MD; Tad Archambault, PhD Effectiv...

More updates from Organogenesis Holdings Inc.